FITC-MSLN-tandem CAR T cells + amph-FITC vaccine

**FITC-MSLN-tandem CAR T cells + amph-FITC vaccine** is an experimental combination immunotherapy for **mesothelin (MSLN)-positive solid tumors**. It pairs **tandem CAR T cells** engineered with FITC (fluorescein isothiocyanate) and MSLN-targeting domains for dual antigen recognition with an **amph-FITC vaccine** (amphiphilic FITC-conjugated vaccine) to boost immune responses. The CAR T cells target MSLN, a cell surface antigen overexpressed in cancers like mesothelioma, ovarian, pancreatic, and gastric tumors, enabling specific cytotoxicity via T cell activation, cytokine release (e.g., IFN-γ, IL-2, TNF-α), and tumor cell lysis. The amph-FITC vaccine likely enhances CAR T efficacy by promoting FITC-specific T cell responses, epitope spreading, or vaccination against FITC-tagged targets, addressing challenges like antigen heterogeneity and immunosuppressive tumor microenvironments (TME) in solid tumors. Preclinical evidence from MSLN CAR T studies shows superior antitumor activity in orthotopic models (e.g., gastric, ovarian, colorectal liver metastases, pancreatic), with improved infiltration, TME reprogramming (e.g., increased CD8+ T cells, reduced MDSCs/Tregs), and synergy via regional delivery or combinations. No specific developer or clinical trial data identified for this exact construct; related MSLN CAR Ts are in early phases for solid tumors.